Rubicor Medical
Founded Year
1998Stage
Series C | DeadTotal Raised
$30MLast Raised
$30MAbout Rubicor Medical
Rubicor Medical is a private medical device company located in Redwood City, California. Our proprietary biopsy technology (Ovation Breast Biopsy Device) is a dramatic improvement over current minimally invasive biopsy technologies. The Ovation system is comprised of a 14-gauge biopsy device capable of excising, capturing and extracting an intact 2.5 cm diameter tissue sample. Ovation is compatible with either ultrasound or stereotactic image guidance. Rubicor was co-founded by Dr. James Vetter and has been privately funded by a consortium of individual investors. James W. Vetter, M.D., CEO and Chairman of the Board, is a board certified interventional cardiologist. He is an Associate Professor of Clinical Medicine at Stanford University Hospital, where he is currently on Active Staff status as community faculty. Dr. Vetter is a graduate of the Medical College of Wisconsin where he completed a residency in internal medicine and a fellowship in cardiology. Dr. Vetter completed an interventional cardiology fellowship with Dr. John Simpson M.D./PhD., at Sequoia Hospital, Redwood City, California. Dr. Vetter is a member of the Alpha Omega Alpha Honor Society and the American College of Cardiologists. He has published six articles and several book chapters as well as over 35 abstracts. Dr. Vetter has held positions as a member of the Physician Advisory Council and/or board member with a number of medical device companies including Guidant, Lumend, Fox Hollow and CardioVasc. He is also a board member of Magellan Systems International, Inc. Dr. Vetter has extensive experience in working with new medical device concepts and designs, working with R&D engineers to develop working prototypes and clinically testing and refining those products. He was co-founder of Perclose and was involved with that company from inception to initial public offering and eventual sale to Abbott Labs. He is a "hands on" clinician with access to resources and expertise needed to build a successful medical device and company. Dr. Vetter has had a number of patents issued in his name as co-inventor. Ary Chernomorsky, V.P. of R&D since 2000 has over 23 years experience in the medical device industry. Prior to joining Rubicor, Mr. Chernomorsky was employed by the Vascular Therapies division of US Surgical Company (acquired by Tyco International), where he served as a Director of R&D. Mr. Chernomorsky has been involved with various startup companies in the R&D Director and Manager capacities including: PAS Inc. (acquired by USS), Advanced Surgical, Inc. (acquired by Imagyn), Micro Therapeutics, Bausch and Lomb, Mentor Corporation and Dart Industries Inc. Ary holds an M.S. in Polymer Engineering from LIT and an M.S. in Biomedical Engineering from Rutgers University. Tony Difede, CPA, V.P. Finance holds a BSBA degree in Accounting from the University of Florida and a M.S. in Taxation from Pace University. He has held management positions in tax and accounting with Ernst & Young, KPMG and my CFO, Inc. His clients have included closely held start-up companies as well as large multinational public corporations. He is licensed in California and New Jersey. He has extensive experience in accounting for stock options and issues regarding closely held companies and their high net worth owners and investors. COMPANY INFO MANAGEMENT page 1 2006 Company Overview (Continued) Breast care. Completely redefined. James W. Vetter, M.D., Founder and Chairman of the Board, is a board certified interventional cardiologist. He is an Associate Professor of Clinical Medicine at Stanford University Hospital, where he is currently on Active Staff status as community faculty. Dr. Vetter is a graduate of the Medical College of Wisconsin where he completed a residency in internal medicine and a fellowship in cardiology. Dr. Vetter completed an interventional cardiology fellowship with Dr. John Simpson M.D./PhD., at Sequoia Hospital, Redwood City, Cal
Rubicor Medical Patents
Rubicor Medical has filed 12 patents.

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
12/30/2009 | 5/1/2012 | Investment funds, Spinning, Dermal and subcutaneous growths | Grant |
Application Date | 12/30/2009 |
---|---|
Grant Date | 5/1/2012 |
Title | |
Related Topics | Investment funds, Spinning, Dermal and subcutaneous growths |
Status | Grant |
Rubicor Medical Frequently Asked Questions (FAQ)
When was Rubicor Medical founded?
Rubicor Medical was founded in 1998.
Where is Rubicor Medical's headquarters?
Rubicor Medical's headquarters is located at 600 Chesapeake Drive, Redwood City.
What is Rubicor Medical's latest funding round?
Rubicor Medical's latest funding round is Series C.
How much did Rubicor Medical raise?
Rubicor Medical raised a total of $30M.
Who are the investors of Rubicor Medical?
Investors of Rubicor Medical include Safeguard Scientifics and ITX International.
Who are Rubicor Medical's competitors?
Competitors of Rubicor Medical include JJET, Linkage Biosciences, Aviir, VitaPath Genetics, Nodality and 9 more.
Compare Rubicor Medical to Competitors
JJET is committed to the development, production, and sales of products in the field of electrophysiology; the products mainly include a three-dimensional cardiac mapping system, multi-channel physiological recorder, cardiac electrophysiological stimulator, cardiac radiofrequency ablation device, cold saline perfusion pump, cardiac electrophysiological mapping catheter, cardiac radiofrequency ablation catheter, nerve radiofrequency treatment instrument. The company was founded in 1991 and is based in Chengdu, China.
Flex Biomedical is developing technologies to treat and diagnose orthopedic diseases. Flex Biomedical's lead product is a synthetic polymer, the Flex Polymer, designed to treat osteoarthritis.
Litholink offers metabolic evaluations for kidney stone formers.
XEPTAGEN SpA is engaged in the discovery and validation of molecular markers in order to produce diagnostic kits for the early detection, monitoring, and screening of cancerous cells. By exploiting the natural immune response to early stage cancer and the platform technology Combinatorial Proteomic, XEPTAGEN has discovered specific tumor markers that lead to an earlier and much more accurate detection of developing carcinomas. The company's mission includes creating tools that improve the diagnostic accuracy for cancer and the clinical management of cancer patients.
Nodality is focused on developing highly predictive tests to enable biologically-informed clinical treatment decisions in patients with cancer and autoimmune disease.
StageMark is a healthcare company that intends to provide an early identification and monitoring solution for inflammatory diseases such as lupus.